Hydrogen sulfide (H₂S) donors represent an emerging therapeutic approach for [Parkinson's Disease](/diseases/parkinsons-disease) that leverages the endogenous gasotransmitter's potent antioxidant, anti-inflammatory, and mitochondrial protective properties. While a general page on [H₂S-releasing compounds](/therapeutics/h2s-releasing-compounds) exists, it lacks dedicated [Parkinson's Disease](/diseases/parkinsons-disease) therapeutic content despite growing preclinical evidence supporting H₂S-based interventions for dopaminergic neuroprotection.
Biological Rationale
Endogenous H₂S in the Brain
H₂S is produced endogenously in the brain through three primary enzymatic pathways:
...
H₂S-Releasing Compounds Therapy for Parkinson's Disease
Hydrogen sulfide (H₂S) donors represent an emerging therapeutic approach for [Parkinson's Disease](/diseases/parkinsons-disease) that leverages the endogenous gasotransmitter's potent antioxidant, anti-inflammatory, and mitochondrial protective properties. While a general page on [H₂S-releasing compounds](/therapeutics/h2s-releasing-compounds) exists, it lacks dedicated [Parkinson's Disease](/diseases/parkinsons-disease) therapeutic content despite growing preclinical evidence supporting H₂S-based interventions for dopaminergic neuroprotection.
Biological Rationale
Endogenous H₂S in the Brain
H₂S is produced endogenously in the brain through three primary enzymatic pathways:
Cystathionine β-synthase (CBS): Primarily expressed in astrocytes, highly sensitive to vitamin B6 status
Cystathionine γ-lyase (CSE): Predominantly in endothelial cells and neurons
3-mercaptopyruvate sulfurtransferase (3-MST): Mitochondria-based production, particularly in neurons
These enzymes convert [cysteine](/amino-acids/cysteine) to H₂S, which acts as a gaseous signaling molecule at nanomolar to micromolar concentrations.
H₂S Dysregulation in PD
Multiple lines of evidence demonstrate H₂S system impairment in [Parkinson's Disease](/diseases/parkinsons-disease):
CBS deficiency: Post-mortem studies show reduced CBS expression in [substantia nigra](/cell-types/dopaminergic-neurons) of PD patients[@xie2023]
Impaired H₂S signaling: Decreased H₂S bioavailability in plasma and CSF of PD patients
Correlation with severity: Lower H₂S levels correlate with more severe motor symptoms
Genetic links: CBS polymorphisms associated with increased PD risk
Mechanisms of Neuroprotection
Mermaid diagram (expand to render)
Therapeutic Compounds
GYY4137
GYY4137 is a slow-releasing H₂S donor that provides sustained, physiological H₂S concentrations:
Current stage: Preclinical to early Phase I transition
Challenges:
BBB penetration of H₂S donors
Optimal dosing for CNS delivery
Sustained vs. pulsatile H₂S release
Opportunities: Combination with [L-DOPA](/therapeutics/dopamine-agonists-parkinsons) or [CoQ10](/therapeutics/coq10-parkinsons)
Therapeutic Development Pipeline
Mermaid diagram (expand to render)
Combination Therapy Potential
H₂S donors show particular promise in combination approaches:
With dopaminergic drugs: May reduce L-DOPA-induced dyskinesias
With mitochondrial agents: Synergy with [CoQ10](/therapeutics/coq10-parkinsons), [Mitochondrial dynamics modulators](/therapeutics/mitochondrial-dynamics-modulators-parkinsons)
With antioxidants: Amplified Nrf2 pathway activation with [Sulforaphane](/therapeutics/sulforaphane-nrf2-neuroprotection)
With anti-inflammatory: Enhanced neuroinflammation control with [NLRP3 inhibitors](/therapeutics/nlrp3-inhibitors-parkinsons)
Challenges and Future Directions
Key Challenges
BBB penetration: Many H₂S donors have limited CNS exposure
Dosing optimization: Balancing efficacy with H₂S toxicity at high concentrations
Targeted delivery: Mitochondrial targeting (like AP39) may be superior
Sustained release: GYY4137 shows promise; newer donors in development
Biomarker development: Need markers to track H₂S activity in brain
Emerging Approaches
Caged H₂S donors: Light-activated release for spatial control
H₂S-NO hybrids: Dual gasotransmitter donors
CBS activators: Upregulate endogenous H₂S production
DMSA analogs: Sulfane sulfur donors with different mechanisms
Related Pages
[H₂S-Releasing Compounds (General)](/content/therapeutics/h2s-releasing-compounds.md) — General therapeutic class
[Gasotransmitter Signaling in Neurodegeneration](/mechanisms/hydrogen-sulfide-signaling-neurodegeneration) — Molecular mechanisms
[Mitochondrial Dynamics Modulators for PD](/therapeutics/mitochondrial-dynamics-modulators-parkinsons) — Related mitochondrial approaches
[Antioxidant Therapies for PD](/therapeutics/antioxidant-therapies-parkinsons) — Related oxidative stress approaches
[NLRP3 Inhibitors for PD](/therapeutics/nlrp3-inhibitors-parkinsons) — Related anti-inflammatory approaches
[CoQ10 for PD](/therapeutics/coq10-parkinsons) — Related mitochondrial cofactor